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 Abstract 
Actinic keratosis (AK) is a chronic skin disease in which multiple clinical and 
subclinical lesions co-exist across large areas of sun-exposed skin, resulting in field 
cancerisation. Lesions require treatment because of their potential to transform into 
invasive squamous cell carcinoma. This article aims to provide office-based 
dermatologists and general practitioners with simple guidance on AK treatment in 
daily clinical practice to supplement existing evidence-based guidelines. Novel 
aspects of the proposed treatment algorithm include differentiating patients 
according to whether they have isolated scattered lesions, lesions clustered in small 
areas or large affected fields without reference to specific absolute numbers of 
lesions. Recognising that complete lesion clearance is rarely achieved in real-life 
practice and that AK is a chronic disease, the suggested treatment goals are to 
reduce the number of lesions, to achieve long-term disease control and to prevent 
disease progression to invasive squamous cell carcinoma. In the clinical setting, 
physicians should select AK treatments based on local availability, and the 
presentation and needs of their patients. The proposed AK treatment algorithm is 
easy-to-use and has high practical relevance for real-life, office-based dermatology.  
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 Introduction 
Actinic keratosis (AK) is a chronic skin lesion, which principally arises due to long-
term sun-exposure (1-3). As ultraviolet radiation affects the entire sun-exposed area 
of skin, clinically visible AK lesions are surrounded by subclinical or invisible lesions 
resulting in field cancerisation (Figure 1) (4,5). AK lesions can be considered as early 
in situ squamous cell carcinoma (SCC) and part of a disease continuum that can 
progress into invasive SCC (1-3). Furthermore, subclinical and early AK lesions may 
also be associated with invasive SCC, suggesting that these lesions may also 
directly transform into invasive disease (6). Estimates from clinical studies indicate 
that 0.025–16% of AK lesions may progress to invasive SCC per year (7), although 
there are currently no established biomarkers to predict which subclinical or clinical 
lesions will progress and when this progression will occur. However, based on 
clinical experience, it is evident that there is an association between AK lesions and 
invasive SCC, which is stronger with a greater number of AK lesions, suggesting a 
risk of transformation (8). Consequently, guidelines recommend that all AKs need to 
be adequately treated (9). 
 The prevalence of AK and the clinical and economic burden of the disease 
are expected to rise substantially over the coming decades (10,11). This is because 
AK mainly affects elderly people who have had chronic lifetime sun exposure [with 
an estimated prevalence of 34% of men and 18% of women in Europe aged over 70 
years (12)], and due to the increasingly ageing global population. The prevalence of 
the disease varies widely between different countries with the highest prevalence 
seen in Australia (40–60% of adults) (13). In some countries, AK is considered to be 
an occupational disease for those who work outside (14). Other risk factors for the 
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 development of AK include male gender, fair skin type and immunosuppression (15-
17). 
 The recently published global S3 guidelines from the International League of 
Dermatological Societies (ILDS) and European Dermatology Forum (EDF) provide 
evidence-based recommendations for the treatment of AK (9). Published data from 
randomised clinical trials (RCTs) are considered to be the ‘gold-standard’ evidence 
to support treatment recommendations. However, these RCTs typically include a 
highly selected homogeneous population of patients due to their strict eligibility 
criteria and may not be representative of the broader range of AK patients seen by 
dermatologists in real-life clinical practice.  
In addition to evidence-based guidelines, there is a need to provide 
dermatologists with simple, practical, easy-to-use guidance on the treatment of AK in 
daily clinical practice. Recognising this need, the aim of this article is to provide a 
real-world practical approach to the office-based management of AK patients by 
dermatologists and general practitioners (GPs), including guidance on diagnosis, 
patient classification and treatment. The focus of the article is for office-based 
dermatology given that most AK patients are treated in an outpatient setting. In such 
a setting, the availability of devices to perform procedures such as standard 
photodynamic therapy (PDT) is limited, so the main emphasis is on topical AK 
treatments which can be self-applied by the patient. The aim is not to replace current 
treatment guidelines, but to provide complementary practical advice on the treatment 
of AK in daily clinical practice.  
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 Methods 
An international panel of fourteen experts in AK was convened to develop a real-
world practical approach to AK management. The practical guidance was developed 
based on a review of published international and national guidelines on AK, together 
with an evaluation of relevant literature published up to June 2016. In situations 
where insufficient published information was available and where published 
information was not considered to be relevant to real-life practice, recommendations 
were developed based on consensus of the author’s practical clinical experience. 
 
AK diagnosis 
AK is easy to diagnose and commonly seen by office-based dermatologists (18). 
However, the disease is often underestimated by patients who typically are not 
aware of the potential risk of malignant transformation (10,19). Consequently, AK is 
frequently diagnosed when patients present for other skin diseases. In elderly 
patients with clear evidence of photodamaged skin, physicians should check for the 
presence of AK in sun-exposed areas, irrespective of the reason for the consultation. 
 The majority of AKs are diagnosed based on clinical examination and a 
history of risk factors. AK lesions present as rough scaly patches, plaques or papules 
on an erythematous base in an area, which shows signs of chronic sun damage. The 
lesions are usually <1 cm in size and have a sandpaper-like texture on palpation 
(1,9). 
 AK lesions may be clinically graded on the basis of their thickness using the 
Olsen classification system (20). Grade 1 lesions are slightly palpable, grade 2 
lesions are moderately thick, and grade 3 lesions are very thick and hyperkeratotic 
(Figure 2) (20). This grading was proposed to provide a better characterisation of 
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 disease and to distinguish different morphological subtypes. However, a recent study 
showed that the clinical classification of lesions using this system does not reliably 
provide information on the underlying histology of the lesions, with only 
approximately 50% of lesions having matching clinical and histological classifications 
(21). Therefore, the Olsen classification cannot be used as a surrogate marker of 
histopathology. Moreover, the two types of classification systems provide different 
information on AK lesions. For example, lesions clinically classified as grade 3 are 
hyperkeratotic, whereas those classified histologically as grade III are in situ SCC 
(20,22). 
 Dermoscopy improves the clinical diagnosis of AK and has been reported to 
reach a 98.7% and 95.0% diagnostic sensitivity and specificity, respectively (23). 
Depending on the clinical aspects, dermoscopy reveals either a red network pattern 
(grade 1), a “strawberry pattern” (grade 2), or structureless white to yellow areas 
(grade 3) (Figure 2) (23,24). Moreover, dermoscopy can aid in the assessment of 
treatment response (Figure 3) and in the differential diagnosis of AK versus other 
benign non-melanocytic lesions such as solar lentigo or seborrheic keratosis. In the 
case of pigmented AK, dermoscopy may help to rule out lentigo maligna (24). 
Dermoscopy can also help to identify early signs of invasive SCC due to the 
presence of vessels or white circles, which are rarely observed in AK (25). 
 A skin biopsy should be taken to rule out differential diagnoses and if one or 
more of the following clinical features are present which may indicate invasive SCC 
or other types of skin cancer: infiltration, induration, ulceration, pigmentation, rapid 
enlargement and pain (9). A biopsy should be considered if coiled/dotted, hairpin or 
polymorphous vessels and/or white circles or whitish homogeneous areas are 
detected with dermoscopy (25). Biopsies are also required in patients where clinical 
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 clearance cannot be achieved and a suspicious lesion remains. In the future, novel 
imaging techniques such as reflectance confocal microscopy and optical coherence 
tomography may be useful in the diagnosis of AK (5,26,27). 
 Following diagnosis, the dermatologist or GP should provide patients with a 
simple explanation about AKs – describing them as sun-damaged skin and a marker 
for invasive skin cancer and avoiding the term, “precancerous” – so that they 
understand the possibility of malignant transformation and recognise why their 
lesions need to be treated. Clinical and dermoscopy photographs of the lesions and 
treatment area are useful to allow the clinician to monitor the treatment response and 
for clinical documentation of the patient. The images can be used to explain the 
disease to the patient and to clarify where topical treatment needs to be applied. 
Images can be taken again at every follow-up visit. 
 
Clinical spectrum of AK 
AK patients usually present with multiple clinical lesions rather than isolated 
individual lesions. The latest ILDS/EDF AK guidelines classify patients according to 
the number of AK lesions per affected field or body region. Patients with single 
lesions have ≥1 but ≤5 palpable or visible AK lesions, those with multiple lesions 
have ≥6 distinguishable AK lesions, and those with field cancerisation also have ≥6 
distinguishable AK lesions together with contiguous areas of chronic actinic sun 
damage and hyperkeratosis (9). This classification is used to direct treatment 
choices. 
 The authors consider the ILDS/EDF patient classification to have limited 
supporting evidence for the numerical thresholds of AK lesions which separate the 
different categories of patients, as previously discussed by Pellacani et al. (28). 
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 Whilst the number of AK lesions is useful to define patient eligibility criteria for RCTs, 
it does not provide useful information on the underlying biological characteristics of 
the disease process, in particular field cancerisation. In addition, absolute lesion 
numbers do not take into consideration important factors, such as early recurrence 
after treatment, rapid increase in lesions, immunosuppression or other factors that 
can influence the risk of developing an invasive SCC. 
 The authors propose that AK patients should be classified as follows without 
defining a specific number of AK lesions per patient group: (1) Those with isolated 
individual lesions scattered on separate body areas; (2) Those with multiple AK 
lesions clustered into a single small field; and (3) Those with multiple lesions across 
a large field such as the entire face or scalp (Figure 4).  
The authors also consider it to be important to identify patients who are at 
high risk of progression to invasive SCC or metastatic disease so that they can be 
monitored more closely. Criteria suggestive of “high-risk” patients are shown in Table 
1, although there is currently limited supporting evidence for identifying those most 
likely to progress to invasive disease.  
 
Practical algorithm for AK management 
A practical algorithm for the management of AK patients in real-life clinical practice is 
shown in Figure 5. Following a clinical diagnosis of AK, it is advisable to remove any 
hyperkeratosis (e.g., with curettage, laser ablation, keratolytic treatment) before 
initiating treatment. Curettage is preferred because it allows histological confirmation 
of the diagnosis. Furthermore, the panel recommends taking biopsies and 
performing histopathology on residual lesions after topical treatment to explore the 
possibility of malignancy. 
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 Treatment recommendations are provided for patients with isolated scattered 
lesions, those with small clusters of lesions and those with involvement of large 
areas. Lesion-directed therapies are those that are suitable for the treatment of 
single scattered lesions, but which do not treat the surrounding skin. Cluster-directed 
therapies are those that are suitable for the treatment of small field cancerisation 
areas (usually ≤25 cm2) based on their licensed indication. Cluster-directed therapies 
may also be used to treat larger fields in successive treatment cycles, although this 
comes at the expense of an increased number of physician visits and longer 
treatment durations as subsequent cycles can only be started after the initial cycle 
has been completed and a rest period has been taken. Therapies for large-affected 
fields are those that are suitable for the treatment of sun-exposed fields >25cm2. 
These therapies may also be used for the treatment of clustered lesions in small 
fields. 
 
AK treatment goals 
The goals of AK treatment are to eradicate as many clinical and subclinical AK 
lesions as possible (i.e., to reduce the extent of field cancerisation), to achieve a time 
to relapse or disease-free interval that is as prolonged as possible, and to decrease 
the risk of a patient developing invasive SCC. Secondary aims are to improve the 
quality of the patient’s skin and consequently their quality of life. Since it is not 
always possible to clear each AK lesion in real-life practice, the main aim of therapy 
is to reduce the number of lesions and to achieve long-term disease control. AK is a 
marker for chronic sun damage, another goal of AK treatment is to reduce the risk of 
other UV-dependent skin cancers.  
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  In real-life clinical practice, treatment success should usually be evaluated 
using the absolute or percentage reduction in AK lesions, rather than by determining 
whether or not the patient achieves complete clearance. For example, a patient with 
20 AK lesions on clinical presentation and one lesion remaining after field-directed 
treatment may be considered a treatment failure based on the endpoint of complete 
lesion clearance, even though a 95% reduction in lesions has been achieved. 
Treatment success parameters should ideally also take into consideration the ability 
of a therapy to eliminate subclinical lesions, though this depends on these lesions 
becoming detectable during treatment, or the use of specific imaging techniques for 
field cancerization (which are not usually available in dermatological offices) (26). 
 The authors do not specify a particular percentage reduction of lesions, which 
corresponds to treatment success in daily practice, since this will depend on the 
number of lesions the patient has on presentation and the individual clinical situation. 
Instead, the dermatologist/GP should evaluate whether treatment success has been 
achieved, recognising that complete lesion clearance is rarely attained in real-life 
practice. Clinical photographs at initial and follow-up visits are recommended to 
evaluate the treatment response, particularly in patients with multiple lesions.  
Patients should be followed-up 3–6 months after completion of treatment to 
determine the success of the therapy and to exclude early disease relapse. If there is 
rapidly evolving disease, patients should be treated with a different AK regimen. If 
treatment success has been achieved, the patient can be followed-up subsequently 
every 6–12 months. 
The goals of AK treatment may need adaptation according to the clinical 
situation. For example, for lesions which are at a high risk of progressing to invasive 
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 SCC such as those on the ear, lip and eyelid (29,30), the goal of treatment should be 
complete lesion clearance. 
 
Other management recommendations 
Dermatologists/GPs should advise all AK patients to protect themselves from 
sunlight. In particular, patients should regularly use a high sun protection factor 
(≥50), broad-spectrum sunscreen. Patients should be advised to avoid sun exposure 
between 11 am and 3 pm, and to protect themselves from sunlight whilst outside by 
wearing sunglasses, a brimmed hat and loose fitting clothing.  
 The authors recommend that certain AK patients (e.g., immunocompromised 
patients; patients with AK around the eyelid or in other sensitive areas) should be 
referred to specialised centres for treatment. In the case of extensive disease, a 
blood count to exclude chronic lymphocytic leukaemia or other diseases which lead 
to immunosuppression is recommended (31), since these patient populations also 
need special attention. 
 
Comparison of AK treatment options 
Treatment considerations 
When selecting an AK treatment, the dermatologist/GP has to take into consideration 
patient-, lesion- and treatment-related factors. Patient-related factors include age 
(many AK patients are often elderly with age-related health problems and co-
morbidities), their ability to perform home-based treatment, their quality of life, and 
whether they adhere to the regimen (32-34). Lesion-related factors include the 
number of lesions as well as their location and presentation. Treatment-related 
factors include treatment duration, application scheme, efficacy, cost, side-effects 
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 and prior therapies. Treatment selection also depends on their availability in different 
practices and countries. Dermatologists/GPs should select AK treatments which they 
are experienced in using. 
 Adherence with AK treatments is currently poor with approximately 90% of 
patients being non-adherent or non-persistent with therapy (35). Dermatologists/GPs 
need to advise patients about the importance of using their treatment and how to 
apply it correctly to ensure that adherence is optimised. For example, patients need 
to understand that field-directed treatment should be applied not only to visible 
lesions, but also to the entire surrounding sun-exposed area. Dermatologists/GPs 
should also ensure that patients are aware of any anticipated local skin reactions 
during treatment. Features of an AK treatment which may optimise patients’ 
adherence are short and simple treatment regimens, ability to self-apply, good 
efficacy and tolerability, lack of pain, and easy access for patients in terms of cost 
and reimbursement issues (36-38). 
 AK treatments, which may be used by office-based dermatologists and GPs, 
are compared in Table 2 and discussed in more detail below. 
 
Lesion-directed therapies 
Physical treatments 
Cryotherapy is widely available and commonly used in office-based dermatology for 
the destruction of single AK lesions with liquid nitrogen. The technique rapidly 
removes individual clinical lesions, but does not treat field cancerisation or 
subclinical lesions in the surrounding area and is associated with high rates of 
disease recurrence of up to 96% within one year (39). The main side effects of 
cryotherapy are pain, stinging, and burning during treatment. Poor cosmetic 
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 outcomes, in particular hypopigmentation after healing (which is directly correlated 
with freezing times) are a disadvantage of this treatment (40). There is also a lack of 
standardisation in how the procedure is performed. According to the authors, 
cryotherapy is an option for single lesions on the scalp and dorsum of the hands. 
However, relapse rates after cryotherapy are high, and efficacy can be impaired by 
hyperkeratosis since it may reduce the cold penetration into the tissue (41). The 
authors also recommend that field-directed treatment should be performed after 
cryotherapy. 
 Other physical treatments which target individual clinical AK lesions include 
curettage, excision and laser therapy (42). There is less clinical evidence supporting 
the use of these treatments than for cryotherapy and some are associated with poor 
cosmetic outcomes and/or need sophisticated equipment and appropriate training. 
 
Cluster-directed therapies 
0.5% 5-fluorouracil / 10% salicylic acid 
0.5% 5-fluorouracil / 10% salicylic acid solution may be used for the treatment of 
individual or small clusters of lesions. The 5-fluorouracil component inhibits RNA and 
DNA synthesis in rapidly dividing cells to preferentially target AK lesions over normal 
skin cells. The salicylic acid component decreases the hyperkeratosis associated 
with AK. The treatment is indicated for both slightly palpable and/or moderately thick 
hyperkeratotic lesions (but not Olsen grade 3 lesions) and is self-applied by the 
patient once-daily for a maximum of 12 weeks (43). The treatment is applied directly 
to AK lesions, and therefore, does not treat subclinical lesions in the surrounding 
field. Some patients, particularly elderly people, may have difficulties in precisely 
applying the liquid with a brush applicator to the treatment area. Studies have shown 
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 that 0.5% 5-fluorouracil / 10% salicylic acid leads to a 70–75% reduction in AK 
lesions (44,45). Commonly reported side effects include application site irritation and 
inflammation (44). 
 
Imiquimod 5% 
Imiquimod is an immune response modifier, which acts as a Toll-like receptor-7 
agonist. It stimulates the local production of cytokines in the epidermis that enhance 
cellular immunity and also has a direct apoptotic effect on tumour cells (46-48). 
 Imiquimod 5% cream may be used for the treatment of small clusters of 
lesions (in an area ≤25 cm2). The treatment is self-applied by patients three times a 
week on alternate days for four weeks. After a four-week treatment-free interval, a 
second course of treatment may be initiated if the patient still has residual lesions. 
Imiquimod 5% may also be used to treat field cancerisation in sequential treatment 
courses, although this results in a long overall treatment duration since there should 
be a rest period between courses (4–8 weeks), and may be associated with a high 
overall treatment cost. 
 Clinical studies have shown that imiquimod 5% can detect and clear clinical 
and subclinical lesions, with a clearance rate of individual clinical lesions of 
approximately 75% (5,49,50). Disease recurrence rates are low since both clinical 
and subclinical disease are targeted, with studies reporting recurrence in 27% of 
patients after 12 months of follow-up (which was substantially lower than with 5-
fluorouracil [67%] and cryotherapy [96%] in the same study) (39), in 25% of patients 
after 16 months (51) and 20% of patients after 24 months (52). Imiquimod 5% has 
also demonstrated efficacy against superficial basal cell carcinoma (BCC), small 
nodular BCC and Bowen’s disease (53-59). Commonly reported side effects are 
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 inflammatory local skin reactions, which may extend beyond the treatment area 
(49,50,60). Systemic side effects such as flu-like symptoms occur rarely (60). 
 
Ingenol mebutate 
Ingenol mebutate is believed to have two mechanisms of action including stimulation 
of immune responses mediated by neutrophils and induction of necrosis of dysplastic 
cells. Its exact mechanism of action, however, is not completely clear (61,62). It is 
available as a 0.05% gel to treat AK lesions located on the trunk or extremities and 
as a 0.015% gel for the face and scalp. Both ingenol mebutate concentrations may 
be used for the treatment of small clusters of lesions in an area of 25 cm2, with the 
therapy applied on two (0.015%) or three (0.05%) consecutive days. The short 
treatment duration leads to high patient adherence with the regimen (60,63). Large 
affected fields may be treated in successive cycles, although this results in long 
overall treatment durations (as treatment courses need to be separated by an eight-
week rest period) and high costs. 
The results of four RCTs of ingenol mebutate showed that this AK treatment is 
associated with median reductions of clinical lesions of 75–83% eight weeks after 
treatment was completed (63). Out of the patients cleared of lesions at the end of the 
initial studies, 50–54% had disease recurrence in the treatment field during one year 
of follow-up (63). Intense local skin reactions such as erythema, flaking/scaling and 
crusting commonly occur (63,64). These side effects predictably occur in the week 
following treatment and resolve within 2–4 weeks (60).  
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 Large field-directed therapies 
Imiquimod 3.75% 
Imiquimod 3.75% cream can be used to treat large affected fields (i.e., full face or 
balding scalp) in one treatment course. Imiquimod 3.75% is applied daily in a simple 
regimen consisting of 2 two-week treatment cycles, separated by a two-week 
treatment free interval. It has a strong recommendation for the treatment of multiple 
AK and field cancerisation in the ILDS/EDF S3 treatment guidelines with the highest 
percentage of agreement between experts (≥90%) of any field-directed AK therapy 
(9). Small clusters of lesions may be treated with imiquimod 3.75% or 5%. 
 The results from RCTs of imiquimod 3.75% have shown that this field-directed 
treatment leads to an 81.8% median percentage reduction in AK lesions from 
baseline (65). The appearance of lesions clinically similar to AKs on the treated area, 
which subsequently disappear during the treatment course, suggests that imiquimod 
3.75% may detect and treat both clinical and subclinical lesions (5,65-67). An 
additional analysis of data from the RCTs showed that imiquimod 3.75% leads to a 
92.2% median percentage reduction in lesions from Lmax (maximum lesion count 
during treatment) to study end (66). The AK lesion reduction with imiquimod 3.75% is 
also sustained over the long-term (68,69).  
 The most common side effects with imiquimod 3.75% are local skin reactions, 
which may extend beyond the treatment area (60). These reactions, in particular 
erythema, indicate that the treatment is having a beneficial effect (65,70). Rest 
periods may be taken during either of the two treatment cycles in order to manage 
local skin reactions, if required, with no impact on efficacy (71). As for imiquimod 5%, 
rare systemic reactions may occur during treatment with imiquimod 3.75% (72). 
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 5% 5-fluorouracil 
Five percent 5-fluorouracil cream may be used to treat field cancerisation or small 
clusters of lesions. It leads to cell death by inhibiting thymidylate synthetase, an 
enzyme required for DNA synthesis (60). The treatment is easy for patients to self-
apply twice a day to the affected area over 3–4 weeks and can be used to treat large 
areas (up to 500 cm2) in one treatment course. 
 RCTs have demonstrated an overall lesion clearance rates of 47–88% with 5-
fluorouracil (73-76). Long-term follow-up studies have shown a 12-month disease 
recurrence rate of 67% (39), whereas 82% of patients required a lesion-directed 
treatment for recurrent AKs over a mean follow-up of 2.6 years compared with 89% 
of patients in the control group (75). Comparative clinical studies have indicated that 
5% 5-fluorouracil leads to a greater reduction in AK lesions than diclofenac 3% 
(77,78) and imiquimod 5% (79), and a similar AK lesion reduction to photodynamic 
therapy with aminolevuinic acid (80). 
Five percent 5-fluorouracil is associated with the development of intense, 
unspecific local skin reactions such as inflammation, pruritus, scaling and crusting, 
which may limit the size of the treatment field and reduce patient adherence in daily 
clinical practice (42,73,81). Owing to these intense local skin reactions, studies have 
shown that 5% 5-fluorouracil is less well tolerated than other AK treatments such as 
diclofenac sodium 3% and photodynamic therapy (77,78,80). Exposure to sunlight 
during 5% 5-fluorouracil treatment may increase the intensity of skin reactions (60). 
Another disadvantage is the potential for life-threatening drug interactions with 
inhibitors of dihydropyrimidine dehydrogenase such as brivudine (82).  
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 Diclofenac 3% in 2.5% hyaluronic acid 
Diclofenac is a non-steroidal anti-inflammatory drug which inhibits cyclooxygenase 2. 
Diclofenac 3% gel in 2.5% hyaluronic acid may be used to treat clustered lesions 
and field cancerisation. Although easy to apply, diclofenac has to be applied twice-
daily for 60–90 days (83), and this lengthy treatment duration may be difficult for 
many patients to fully comply with. 
 Some authors consider the efficacy of diclofenac to be lower than other 
topical treatments (9,60), with the treatment being useful for controlling AK rather 
than clearing lesions. The overall lesion clearance rates of 54–63% reported in RCTs 
(84,85) are rarely observed in real-life clinical practice. However, an advantage of 
diclofenac is its good tolerability with only mild irritant side effects such as pruritus, 
erythema and dry skin, and only rare occurrences of contact dermatitis (60,84-87). 
 
Photodynamic therapy (PDT) 
With PDT, the skin is treated with a photosensitising drug (either aminolevuinic acid 
or methyl aminolevulinate) which is preferentially accumulated by rapidly dividing 
atypical keratinocytes. The cells are then eradicated when the skin is exposed to an 
external light source in the presence of oxygen (88). The procedure may be used to 
treat small clusters of lesions or large affected fields, although it is not widely 
available in office-based dermatology. Overall, this physician-administered 
procedure is time-consuming, can cause severe pain, and may be less convenient 
for some patients than self-apply a topical medication. Recent studies have shown 
that daylight PDT is associated with less pain and greater patient satisfaction than 
conventional PDT, although efficacy may vary according to geographical locations, 
weather conditions and seasons (89,90). Daylight PDT is increasingly becoming an 
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 important option to treat AK, since the patients can apply the photosensitising cream 
at home and then expose themselves to the sun, without needing repeat physician 
visits. 
 RCTs have reported overall lesion clearance rates of 82–91% (91-95) and 12-
month disease recurrence rates of 53–64% depending on the type of 
photosensitising agent that is used (96). The procedure can be associated with 
intense local reactions such as erythema, stinging/burning and oedema (97). 
 
Combination approaches 
The treatment approaches described above may be used in combination with each 
other according to the clinical situation and patient response to treatment. A lesion-
directed treatment may be used to target any lesions remaining after a patient has 
been treated with a large field-directed therapy. Alternatively, a lesion-directed 
treatment may be used to clear AK lesions, with a field-directed therapy 
subsequently being used to treat the actinic damage in the surrounding area. As an 
example, a study of the use of imiquimod 3.75% after cryosurgery showed that this 
approach provided significantly greater clearance of AK lesions assessed six months 
after treatment completion compared with cryosurgery followed by placebo (median 
percentage reduction: 86.5% vs 50%, respectively, p<0.0001) (98). Similarly, 
sequential use of other AK treatments such as cryosurgery followed by 5-fluorouracil 
(99) and PDT followed by imiquimod 5% (100) lead to an improvement in AK lesion 
reduction versus a single treatment.   
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 Conclusions and future directions 
This article provides office-based dermatologists and GPs with a simple, practical 
guide for diagnosing AK, classifying patients, and selecting appropriate treatment for 
them in daily clinical practice. The algorithm differentiates patients according to 
whether they have scattered lesions, lesions clustered in small fields, or large fields 
affected by AK, and pragmatically allows physicians to select treatments based on 
their local availability, the clinical presentation of individual patients and patient 
preferences. The suggested therapeutic approach is flexible allowing treatments to 
be used alone or in combination until the goal of treatment, i.e., lesion reduction and 
long-term disease control, is achieved. 
 There are several key areas for future investigations, which would strengthen 
the evidence base on which recommendations for the treatment of AK patients in 
real-life practice are made. For example, studies are needed to define optimal cut-
offs of AK lesions, which separate patients into distinct groups who require different 
treatment approaches. Well-designed, large-scale RCTs comparing different AK 
treatments are urgently required as are studies of AK treatments in real-life clinical 
practice. Long-term studies investigating the effect of AK treatments on the risk of 
disease progression to invasive SCC would also be informative. 
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 Table 1. AK patients at high risk of progression to invasive squamous cell carcinoma 
or metastatic disease. 
Supported by evidence Expert opinion 
 AKs on body areas such as the ear 
and lip (29,30) 
 Early disease relapse following 
treatment (101) 
 Immunocompromised patients (29,30) 
o Elderly 
o Organ transplant recipients 
o Rheumatological disease 
o Haematological disease 
o Inflammatory bowel disease 
o Chronic lymphocytic leukaemia 
 Poor response to treatment 
 High cumulative lifetime sun exposure 
(occupational or recreational) 
 Personal history of skin cancer 
 Many AK lesions 
 Fair skin type 
 Smoking 
 Alcoholism 
 Other diseases affecting patients’ 
immunocompetence 
 
AK, actinic keratosis.  
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 Table 2. Comparison of AK treatments. 
Treatment Lesion-
directe
d 
Cluster-
directe
d 
Large 
field-
directed 
Advantages Disadvantages 
Physical 
treatments 
Cryotherapy 
Curettage 
Lasers 
Yes No No  Rapid 
 Widely 
available 
and used in 
office-based 
dermatology 
 
 Poor 
standardisati
on of 
procedure 
 Poor 
cosmetic 
outcomes 
 Does not 
address 
subclinical 
disease 
 Supporting 
evidence for 
cryotherapy 
only 
0.5% 5-
fluorouracil/10
% salicylic acid 
Yes Yes No  Self-
administratio
n 
 Difficulty in 
self-
application 
 Irritant 
reactions 
 Does not 
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 treat 
subclinical 
lesions 
Imiquimod 5%  No Yes Yes, 
sequentia
l use 
 Efficacy 
 Targeted 
therapy: 
active on 
subclinical 
lesions 
 Also active 
on Bowen’s 
disease, 
superficial 
BCC 
 Long 
treatment 
duration for 
large fields 
(i.e., repeat 
treatments) 
 Inflammator
y reactions 
extending 
beyond 
treatment 
area 
 Rare 
systemic 
reactions 
(e.g., flu-like 
symptoms) 
Ingenol 
mebutate 
No Yes Yes, 
sequentia
l use 
 Efficacy 
 Short 
treatment 
duration for 
clustered 
 Long 
treatment 
duration for 
large fields 
(i.e., repeat 
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 lesions 
 Predictability 
of local skin 
reactions 
 High 
adherence 
 Can be used 
to treat trunk 
and 
extremities 
(in addition 
to face and 
scalp) 
treatments) 
 Intense 
irritant 
reactions 
Imiquimod 
3.75% 
No Yes Yes  Efficacy 
 Can treat 
large field 
(full face or 
balding 
scalp) in one 
treatment 
course 
 Short 
treatment 
duration for 
large field 
 Inflammator
y reactions 
extending 
beyond 
treatment 
area 
 Rare 
systemic 
reactions 
(e.g., flu-like 
symptoms) 
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  Targeted 
therapy: 
active on 
subclinical 
lesions 
 Easy self-
application 
 Personalise
d 
managemen
t 
5% 5-
fluorouracil 
No Yes Yes  Easy self-
application 
 Can treat 
large field in 
one 
treatment 
course 
 Intense, 
unspecific 
local 
reactions  
 Possible 
drug 
interactions 
(e.g., 
brivudine) 
Diclofenac 3% 
in 2.5% 
hyaluronic acid 
No Yes Yes  Easy self-
application 
 Good 
tolerability 
 Long 
treatment 
duration 
 Poor 
adherence  
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  Low efficacy 
Photodynamic 
therapy 
No Yes Yes  Efficacy 
 
 Availability 
in office-
based 
dermatology 
 Cannot be 
self-applied 
 Intense local 
reactions 
 Pain 
AK, actinic keratosis; BCC, basal cell carcinoma. 
Yes / No, means recommended or not recommended by the authors, respectively. 
Although field-directed therapies may be used to treat individual lesions, the 
recommendations reflect practical considerations and the situation in real-life, office-
based dermatology.  
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 Figure Legends 
Figure 1. Concept of field cancerisation. 
In this image of a severely sun-damaged scalp, clinically and dermoscopically visible 
invasive squamous cell carcinoma (upper right insert), Bowen’s disease (lower right 
insert) and AKs (upper left) co-exist with subclinical lesions that are only seen by 
histopathology (lower left). 
Figure 2. Clinical and dermoscopic grading of AK. 
Left image – grade 1; middle image – grade 2; right image – grade 3. 
Figure 3. Dermoscopy for treatment monitoring. 
Left image – clinical and dermoscopic criteria of AK are present; right image – 
clinical and dermoscopic criteria of AK have disappeared. This also corresponds well 
with histopathological clearance. 
Figure 4. Classification of AK lesions: (A) isolated lesion; (B) multiple lesions 
clustered in a small field; (C) multiple lesions across a large field (entire scalp). 
Figure 5. Practical algorithm for the treatment of AK. 
AK, actinic keratosis; iSCC, invasive squamous cell carcinoma. 
*Pre-treatment (e.g., curettage, laser ablation) to remove hyperkeratosis. 
†Discharge and follow-up patient if treatment success is achieved; move patient to 
different AK treatment if treatment success is not achieved.  
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